MannKind Corporation  

(Public, NASDAQ:MNKD)   Watch this stock  
Find more results for mnkd
7.32
-0.15 (-2.01%)
After Hours: 7.38 +0.06 (0.82%)
Aug 28, 7:40PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.31 - 7.50
52 week 3.80 - 11.48
Open 7.32
Vol / Avg. 4.03M/10.94M
Mkt cap 3.00B
P/E     -
Div/yield     -
EPS -0.66
Shares 402.38M
Beta 1.41
Inst. own 22%
Nov 3, 2014
Q3 2014 MannKind Earnings Release (Estimated) Add to calendar
Sep 9, 2014
Mannkind Corp at Morgan Stanley Healthcare Conference - 12:55PM EDT - Add to calendar
Aug 11, 2014
Q2 2014 Mannkind Corp Earnings Call - Webcast
Aug 11, 2014
Q2 2014 MannKind Earnings Release
Aug 11, 2014
Mannkind Corp and Sanofi SA Announce Global Licensing Agreement for Afrezza� (insulin human) Rapid-Acting Inhaled Insulin Conference Call - Webcast
Jun 17, 2014
MannKind at Wells Fargo Healthcare Conference
Jun 12, 2014
MannKind at Goldman Sachs Healthcare Conference - Webcast
Jun 2, 2014
MannKind at Jefferies Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -127.70% -75.10%
Return on average equity - -
Employees 265 -
CDP Score - -

Address

28903 North Avenue Paine
VALENCIA, CA 91355
United States - Map
+1-661-7755300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. The Company�s product candidate, AFREZZA (insulin human) inhalation powder, is insulin that is in late-stage clinical investigation for the treatment of adults with type I or type II diabetes for the control of hyperglycemia. The AFREZZA inhalation powder is centered on a class of potential of hydrogen (pH)-sensitive organic molecules. AFREZZA utilizes its Technosphere formulation technology. As of December 31, 2011, MannKind had not generated any product revenues. As of December 31, 2011, the AFREZZA clinical program had involved 61 different studies of AFREZZA and over 5,600 adult patients.

Officers and directors

Alfred E. Mann Chairman of the Board, Chief Executive Officer
Age: 88
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Hakan S. Edstrom President, Chief Operating Officer, Director
Age: 64
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew J. Pfeffer CPA Corporate Vice President and Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Juergen A. Martens Ph.D. Corporate Vice President - Technical Operations, Chief Technical Officer
Age: 58
Bio & Compensation  - Reuters
David B. Thomson Ph.D., J.D. Corporate Vice President, General Counsel, Corporate Secretary
Age: 47
Bio & Compensation  - Reuters
Diane M. Palumbo Corporate Vice President - Human Resources
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kent Kresa Lead Independent Director
Age: 76
Bio & Compensation  - Reuters
Ronald J. Consiglio Independent Director
Age: 70
Bio & Compensation  - Reuters
Michael A. Friedman M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
David H. MacCallum Independent Director
Age: 76
Bio & Compensation  - Reuters